PL2282779T3 - Nowe strategie terapeutyczne leczenia choroby Alzheimera i podobnych zaburzeń poprzez modulację komórkowej odpowiedzi stresowej - Google Patents

Nowe strategie terapeutyczne leczenia choroby Alzheimera i podobnych zaburzeń poprzez modulację komórkowej odpowiedzi stresowej

Info

Publication number
PL2282779T3
PL2282779T3 PL09738186T PL09738186T PL2282779T3 PL 2282779 T3 PL2282779 T3 PL 2282779T3 PL 09738186 T PL09738186 T PL 09738186T PL 09738186 T PL09738186 T PL 09738186T PL 2282779 T3 PL2282779 T3 PL 2282779T3
Authority
PL
Poland
Prior art keywords
modulation
related disorders
alzheimer disease
stress response
new therapeutic
Prior art date
Application number
PL09738186T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Oxana Guerassimenko
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of PL2282779T3 publication Critical patent/PL2282779T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09738186T 2008-04-29 2009-04-29 Nowe strategie terapeutyczne leczenia choroby Alzheimera i podobnych zaburzeń poprzez modulację komórkowej odpowiedzi stresowej PL2282779T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4858508P 2008-04-29 2008-04-29
PCT/EP2009/055207 WO2009133142A1 (en) 2008-04-29 2009-04-29 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
EP09738186A EP2282779B1 (en) 2008-04-29 2009-04-29 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response

Publications (1)

Publication Number Publication Date
PL2282779T3 true PL2282779T3 (pl) 2013-08-30

Family

ID=40873444

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09738186T PL2282779T3 (pl) 2008-04-29 2009-04-29 Nowe strategie terapeutyczne leczenia choroby Alzheimera i podobnych zaburzeń poprzez modulację komórkowej odpowiedzi stresowej

Country Status (18)

Country Link
US (1) US8552041B2 (pl)
EP (1) EP2282779B1 (pl)
JP (2) JP5615805B2 (pl)
KR (1) KR101611824B1 (pl)
CN (1) CN102065897B (pl)
AU (1) AU2009242127B2 (pl)
BR (1) BRPI0911518A2 (pl)
CA (1) CA2722314C (pl)
DK (1) DK2282779T3 (pl)
EA (1) EA019571B1 (pl)
ES (1) ES2410930T3 (pl)
IL (1) IL208983A0 (pl)
MX (1) MX2010011880A (pl)
NZ (1) NZ589309A (pl)
PL (1) PL2282779T3 (pl)
PT (1) PT2282779E (pl)
WO (1) WO2009133142A1 (pl)
ZA (1) ZA201008039B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US9493834B2 (en) * 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US8404680B2 (en) * 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
RS53227B (sr) 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
US8701980B2 (en) 2011-10-27 2014-04-22 Veltek Associates, Inc. Air sample tracking system and method
WO2013071119A2 (en) * 2011-11-10 2013-05-16 Genentech, Inc Methods for treating, diagnosing and monitoring alzheimer's disease
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
SI2819664T1 (sl) * 2012-03-01 2017-12-29 Pharnext Novi sestavki za zdravljenje amiotrofične lateralne skleroze
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
AU2014225301B2 (en) * 2013-03-06 2019-05-16 Macquarie University Assay and method for identifying compounds to treat tauopathies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9102645B2 (en) * 2013-03-15 2015-08-11 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
JP2018527016A (ja) * 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
EP3313428A1 (en) * 2015-06-26 2018-05-02 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
WO2017102738A1 (en) 2015-12-13 2017-06-22 Verburgh Kris Methods and compositions to slow down aging in cells and organisms
WO2017171483A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
US10736876B2 (en) 2017-04-24 2020-08-11 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
KR20200014476A (ko) * 2018-08-01 2020-02-11 경북대학교 산학협력단 설폰아마이드 유도체를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
JP2021535180A (ja) * 2018-09-05 2021-12-16 ユニベルシテイト ファン アムステルダム パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用
WO2020150423A1 (en) * 2019-01-16 2020-07-23 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
KR102288613B1 (ko) * 2019-12-05 2021-08-11 대한민국 Atg5를 이용한 경도인지장애 또는 치매의 진단 방법
CN115835862B (zh) * 2020-07-10 2026-01-02 广东横琴新创益生物医药有限公司 治疗阿尔茨海默病的莫达非尼组合
US20230293726A1 (en) * 2020-08-11 2023-09-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for the treatment of wwox associated diseases
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
US20250134895A1 (en) * 2021-08-16 2025-05-01 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN114736959B (zh) * 2022-05-09 2023-09-22 上海市精神卫生中心（上海市心理咨询培训中心） 轻度认知功能损害诊断标志物、试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
EP1006108A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
EP1006112A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
KR20040081123A (ko) * 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
ES2334682T3 (es) * 2004-03-05 2010-03-15 Nycomed Gmbh Nuevo uso para inhibidores de pde5.
CA2570245A1 (en) * 2004-07-02 2006-01-12 Warner-Lambert Company Llc Compositions and methods for treating pathological infections
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
DE102005032625A1 (de) * 2005-07-13 2007-01-25 Saiger, Lothar, Dr. Arzneimittel zur Behandlung neuronaler und/oder neurodegenerativer Erkrankungen
JP2007261962A (ja) * 2006-03-27 2007-10-11 Oita Univ 肺高血圧症に有用なエンドセリン受容体拮抗薬。
CN1879604A (zh) * 2006-05-17 2006-12-20 济南帅华医药科技有限公司 一种含抗生素的缓释注射剂及其应用
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
TW200831479A (en) 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.

Also Published As

Publication number Publication date
JP5615805B2 (ja) 2014-10-29
JP2014205696A (ja) 2014-10-30
DK2282779T3 (da) 2013-05-27
WO2009133142A1 (en) 2009-11-05
PT2282779E (pt) 2013-05-28
NZ589309A (en) 2012-03-30
EP2282779B1 (en) 2013-03-13
ES2410930T3 (es) 2013-07-03
IL208983A0 (en) 2011-01-31
US20120071483A1 (en) 2012-03-22
CA2722314C (en) 2018-01-02
JP2011518865A (ja) 2011-06-30
EP2282779A1 (en) 2011-02-16
MX2010011880A (es) 2011-05-25
EA201071245A1 (ru) 2011-06-30
ZA201008039B (en) 2011-08-31
US8552041B2 (en) 2013-10-08
CA2722314A1 (en) 2009-11-05
CN102065897A (zh) 2011-05-18
KR20110011628A (ko) 2011-02-08
EA019571B1 (ru) 2014-04-30
CN102065897B (zh) 2013-11-13
AU2009242127A1 (en) 2009-11-05
AU2009242127B2 (en) 2014-03-27
KR101611824B1 (ko) 2016-04-12
BRPI0911518A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
ZA201008039B (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
ZA201008037B (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
GB0918546D0 (en) Compounds for treating ophthalmic diseases and disorders
HRP20182147T1 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
HRP20181512T1 (hr) Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja
IL219412A0 (en) New therapeutic approaches for treating alzheimer disease
IL200528A0 (en) Methods of treating ophthalmic diseases
ZA201003497B (en) Methods for treating obesity and obesity related diseases and disorders
IL202611A0 (en) Methods of treating serotonin-mediated diseases and disorders
GB0703909D0 (en) Treatment of anxiety disorders
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL209816A0 (en) Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PT2405928T (pt) Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
IL210558A0 (en) Treatment of anxiety disorders
EP2203174A4 (en) THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0814043D0 (en) The treatment of skin disorders
IL208831A0 (en) Methods of treating ophthalmic disorders
ZA200906883B (en) Methods of treating ophthalmic diseases
HK1160633A (en) Compounds for treating ophthalmic diseases and disorders
HK1144087A (en) Compounds for treating ophthalmic diseases and disorders
ZA201100325B (en) Treatment of anxiety disorders